Evolution Research Group LLC, a privately held, independent clinical research site company in the United States, has promoted Andria Chastain to chief operating officer and the appointment of Paul Greene, PhD as chief business officer, it was reported yesterday.
Chastain has more than 20 years of experience in the clinical research industry and has been with the company since its inception. As COO, she will continue to manage clinical operations and recruitment activities across the company's portfolio of sites, working closely with site directors and principal investigators. She will also continue to be intimately involved with M&A strategy. She earlier served as senior vice president at the company.
Dr Greene joins the company after six years at Syneos Health and 25 years in the CRO and pharmaceutical industries. He has led product development teams and key customer relationships with a specific focus on central nervous system assets. A psychologist with post-doctoral training as an Eli Lilly Fellow, he has deep experience across the spectrum of CNS disorders with notable concentration in mood disorders, schizophrenia, and paediatrics. In his new role, he will lead corporate strategic growth initiatives and relationships, business development, client budgets and contracts, and marketing.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference